Daten zum Projekt
Initiative: | Trilaterale Partnerschaften – Kooperationsvorhaben zwischen Wissenschaftler(inne)n aus der Ukraine, Russland und Deutschland |
---|---|
Bewilligung: | 15.02.2016 |
Laufzeit: | 3 Jahre |
Projektinformationen
Development of novel therapeutic strategies of treating cancer and autoimmune diseases requires discovery of new drugs that allow efficient killing of damaged cells and spare normal tissue. In particular, a special interest is devoted to the development of natural products that can act specifically as anti-cancer drugs affecting selectively cancer cells such as TRAIL and a number of others. A very promising selective inducer of cell death is the protein lactaptin. Lactaptin is a proteolytic fragment of human milk kappa-casein that induces the death of various cultured cancer cells. It has been demonstrated that lactaptin initiates a number of cell death signalling pathways and has tumor-suppressor potential. The focus of the proposal will be to unravel the cell death signaling pathways induced by lactaptin and the mechanisms of cross-talk between cell modalities. To accomplish these goals quantitative biochemistry, high-end mass spectrometry, contemporary analysis of posttranslational modifications, systems biology and mouse models shall be implemented. The studies of the role of lactaptin in cell death networks, might lead to new breakthrough strategies in the contemporary translational research and will be in the center of the current project.
Projektbeteiligte
-
Prof. Dr. Inna Lavrik
Universität Magdeburg
Institut für Experimentelle Innere Medizin
Bereich Translationale Entzündungsforschung
Magdeburg
-
Dr. Yuriy Kit
National Academy of Sciences of Ukraine
The Department of Regulation of Cell Proliferation
Institute of Cell Biology
Drahomanov St. 14/16, 79005, Lviv, Ukraine
Lviv
Ukraine
-
Dr. Vladimir Richter
Russian Academy of Sciences
Siberian Branch
Laboratory of Biotechnology
Novosibirsk
Russland